期刊论文

中文

中国循证心血管医学杂志

1674-4055

2023

15

09

1030-1035+1046

10.3969/j.issn.1674-4055.2023.09.02

81973753:国家自然科学基金 2018JJ2291:湖南省自然科学基金面上项目

本校为第一机构

目的 Inclisiran是一种抑制前蛋白转化酶枯草溶菌素9（PCSK9）合成的小干扰RNA，具有显著降低低密度脂蛋白胆固醇（LDL-C）水平的潜力，这项研究评估了Inclisiran在高胆固醇血症和心血管预后中的效果及安全性。方法 检索中国生物医学文献、中国知网、万方、维普、PubMed、EMbase、the Cochrane Library、Web of Science数据库，时间均从建库至2021月3月，对公开发表的Inclisiran治疗高胆固醇血症的随机对照试验进行荟萃分析和试验序贯分析（TSA），评价Inclisiran的调脂效果和不良事件风险。结果 共纳入了3个RCT，总样本量3660例。与安慰剂相比，Inclisiran能显著降低LDL-C变化率（MD=-50.55,95...

Objective To review systematically the efficacy and safety of inclisiran in hypercholesterolemia treatment and cardiovascular prognosis.Methods The databases of CBM,CNKI,WanFang Data,VIP Database,PubMed,EMbase,the Cochrane Library and Web of Science were retrieved from database establishment time to Mar.2021.The published randomized controlled trials(RCT)related to hypercholesterolemia treatment with Inclisiran were given a Meta-analysis and trial sequential analysis(TSA).The lipid regulating effect of Inclisiran and risks of adverse events wer...